XML 86 R73.htm IDEA: XBRL DOCUMENT
v3.26.1

Stockholders' Equity - Leerink Underwriting (Details) - USD ($) |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Aug. 19, 2025 | Mar. 31, 2026 | Dec. 31, 2025 | Mar. 31, 2026 | Mar. 31, 2025
Stockholders' Equity |  |  |  |  |
Transaction costs |  |  |  | $ 5,710,000 | $ 0
Proceeds from warrant exercises |  |  |  | 13,800,000 |
Series H Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Pre-funded Series G Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Pre-funded Series H Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
2025 Underwriting Agreement |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of common stock shares issued | 71,540,000 |  | 5,000 |  |
Ownership threshold percentage | 19.99% |  |  |  |
Gross proceeds from sale of equity | $ 50,000,000 |  |  |  |
Underwriting discounts and commissions and offering expenses payable | 3,600,000 |  |  |  |
Transaction costs |  | $ 150,000 |  | $ 507,000 |
Net proceeds from sale of equity | $ 46,400,000 |  |  |  |
Underwriting discount percentage | 6.00% |  |  |  |
All cash exercises of warrants, period | 30 months |  |  |  |
Placement agent fee, quarterly payment due period | 5 |  |  |  |
2025 Underwriting Agreement | Series G and Series H Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Warrants, exercise price | $ 0.7 |  |  |  |
Additional gross proceeds available upon exercise of warrants | $ 50,000,000 |  |  |  |
Proceeds from warrant exercises |  | $ 2,500,000 |  |  |
2025 Underwriting Agreement | Series G Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Warrants, exercisable term | 5 years |  |  |  |
Number of warrants exercised |  | 3,570,000 |  |  |
Proceeds from warrant exercises |  |  | $ 3,000,000 |  |
2025 Underwriting Agreement | Series H Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Warrants, exercisable term | 4 years |  |  |  |
Number of warrants exercised |  | 0 | 4,250,000 |  |
Warrants issued |  | 3,570,000 | 4,255,000 |  |
Proceeds from warrant exercises |  |  | $ 3,000,000 |  |
2025 Underwriting Agreement | 2025 Pre-Funded Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Warrants, exercise price | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 |
Number of warrants exercised |  | 1,079,391 | 3,141,003 |  |
Proceeds from warrant exercises |  | $ 1,079 | $ 3,141 |  |
2025 Underwriting Agreement | Pre-funded Series G Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Warrants issued |  | 3,570,000 | 4,250,000 |  |
2025 Underwriting Agreement | Pre-funded Series H Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Number of shares which may be issued upon conversion of warrants | 35,770,000 |  |  |  |
Warrants issued |  |  | 4,250,000 |  |
2025 Underwriting Agreement | Pre Funded Warrants and Series G Warrants |  |  |  |  |
Stockholders' Equity |  |  |  |  |
Combined purchase price of each Pre-Funded Warrant and the accompanying Common Warrants | $ 0.699 |  |  |  |

X
- Definition The amount of additional gross proceeds available upon exercise of warrants. + References No definition available. + Details
Name: | ibio_AdditionalGrossProceedsAvailableUponExerciseOfWarrants
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of warrants or rights issued. + References No definition available. + Details
Name: | ibio_ClassOfWarrantOrRightIssued
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants exercised. + References No definition available. + Details
Name: | ibio_ClassOfWarrantOrRightNumberWarrantsExercised
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed. + References No definition available. + Details
Name: | ibio_OwnershipThresholdPercentage
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of business days following the each calendar quarter within which placement agent fee is required to pay. + References No definition available. + Details
Name: | ibio_PlacementAgentFeeQuarterlyPaymentDuePeriod
Namespace Prefix: | ibio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount for each unit which includes 1 pre-funded warrant and 1 common share warrant. + References No definition available. + Details
Name: | ibio_SaleOfStockPricePerUnitPreFundedWarrantsAndCommonShareWarrants
Namespace Prefix: | ibio_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period during which the Company is obligated to pay placement agent fees related to cash exercises of warrants, measured from the closing of the related transaction, as specified in the underwriting agreement. + References No definition available. + Details
Name: | ibio_UnderwritingArrangementWarrantExerciseRelatedFeeTerm
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received. + References No definition available. + Details
Name: | ibio_UnderwritingDiscountFeePercentage
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1 + Details
Name: | us-gaap_DeferredOfferingCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromWarrantExercises
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesHWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedSeriesGWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedSeriesHWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=ibio_LeerinkUnderwritingAgreement2025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesGAndSeriesHWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesGWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrants2025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsAndSeriesGWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |